RU2009148985A - Стабилизированные аморфные формы иматиниба мезилата - Google Patents
Стабилизированные аморфные формы иматиниба мезилата Download PDFInfo
- Publication number
- RU2009148985A RU2009148985A RU2009148985/15A RU2009148985A RU2009148985A RU 2009148985 A RU2009148985 A RU 2009148985A RU 2009148985/15 A RU2009148985/15 A RU 2009148985/15A RU 2009148985 A RU2009148985 A RU 2009148985A RU 2009148985 A RU2009148985 A RU 2009148985A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- capsule
- composition according
- imatinib mesylate
- mass
- Prior art date
Links
- 229960002411 imatinib Drugs 0.000 title 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 23
- 239000002775 capsule Substances 0.000 claims abstract 22
- 229960003685 imatinib mesylate Drugs 0.000 claims abstract 10
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims abstract 10
- 239000013543 active substance Substances 0.000 claims abstract 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000007962 solid dispersion Substances 0.000 claims abstract 4
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract 2
- 108010010803 Gelatin Proteins 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229920000159 gelatin Polymers 0.000 claims abstract 2
- 239000008273 gelatin Substances 0.000 claims abstract 2
- 235000019322 gelatine Nutrition 0.000 claims abstract 2
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000003801 milling Methods 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 239000004408 titanium dioxide Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Фармацевтическая композиция, содержащая активный агент, стабилизирующий аморфную форму иматиниба мезилата, и аморфный и иматиниба мезилат, необязательно, вместе с, по меньшей мере, одним фармацевтически приемлемым носителем, в которой активный агент выбран из твердых дисперсий, циклодекстриновых комплексов и продуктов совместного измельчения с выбранными эксципиентами. ! 2. Фармацевтическая композиция по п.1, в которой активный агент представляет собой твердую дисперсию. ! 3. Фармацевтическая композиция по п.1, в которой активный агент представляет собой циклодекстриновый комплекс. ! 4. Фармацевтическая композиция по одному из пп.1-3, представляющая собой капсулу. ! 5. Фармацевтическая композиция по п.4, представляющая собой капсулу, содержащую количество стабилизированного аморфного иматиниба мезилата, соответствующее 50 и 200 мг иматиниба мезилата. ! 6. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой оболочка содержит желатин. ! 7. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой оболочка содержит диоксид титана. ! 8. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой оболочка содержит красный оксид железа. ! 9. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой соотношение массы содержимого капсулы и массы оболочки капсулы составляет между около 100:25 и 100:50. ! 10. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой соотношение массы содержимого капсулы и массы оболочки капсулы составляет между около 100:30 и 100:40. ! 11. Фармацевтическая композиция по одному из пп.1-3, представляющая собой табле�
Claims (12)
1. Фармацевтическая композиция, содержащая активный агент, стабилизирующий аморфную форму иматиниба мезилата, и аморфный и иматиниба мезилат, необязательно, вместе с, по меньшей мере, одним фармацевтически приемлемым носителем, в которой активный агент выбран из твердых дисперсий, циклодекстриновых комплексов и продуктов совместного измельчения с выбранными эксципиентами.
2. Фармацевтическая композиция по п.1, в которой активный агент представляет собой твердую дисперсию.
3. Фармацевтическая композиция по п.1, в которой активный агент представляет собой циклодекстриновый комплекс.
4. Фармацевтическая композиция по одному из пп.1-3, представляющая собой капсулу.
5. Фармацевтическая композиция по п.4, представляющая собой капсулу, содержащую количество стабилизированного аморфного иматиниба мезилата, соответствующее 50 и 200 мг иматиниба мезилата.
6. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой оболочка содержит желатин.
7. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой оболочка содержит диоксид титана.
8. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой оболочка содержит красный оксид железа.
9. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой соотношение массы содержимого капсулы и массы оболочки капсулы составляет между около 100:25 и 100:50.
10. Фармацевтическая композиция по п.5, представляющая собой капсулу, в которой соотношение массы содержимого капсулы и массы оболочки капсулы составляет между около 100:30 и 100:40.
11. Фармацевтическая композиция по одному из пп.1-3, представляющая собой таблетку.
12. Фармацевтическая композиция по п.11, представляющая собой таблетку, содержащую количество стабилизированного аморфного иматиниба мезилата, соответствующее 100, 400 или 800 мг иматиниба мезилата.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07109816.4 | 2007-06-07 | ||
EP07109816A EP2000139A1 (en) | 2007-06-07 | 2007-06-07 | Stabilized amorphous forms of imatinib mesylate |
US97419707P | 2007-09-21 | 2007-09-21 | |
US60/974,197 | 2007-09-21 | ||
PCT/US2008/065838 WO2008154262A1 (en) | 2007-06-07 | 2008-06-05 | Stabilized amorphous forms of imatinib mesylate |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009148985A true RU2009148985A (ru) | 2011-08-20 |
RU2489149C2 RU2489149C2 (ru) | 2013-08-10 |
Family
ID=38229765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009148985/15A RU2489149C2 (ru) | 2007-06-07 | 2008-06-05 | Стабилизированные аморфные формы иматиниба мезилата |
Country Status (27)
Country | Link |
---|---|
US (4) | US20100178336A1 (ru) |
EP (2) | EP2000139A1 (ru) |
JP (2) | JP5380440B2 (ru) |
KR (2) | KR101454086B1 (ru) |
CN (2) | CN101678023A (ru) |
AR (1) | AR067328A1 (ru) |
AU (1) | AU2008262059B2 (ru) |
BR (1) | BRPI0812442A2 (ru) |
CA (1) | CA2687741A1 (ru) |
CL (1) | CL2008001658A1 (ru) |
CO (1) | CO6241118A2 (ru) |
CY (1) | CY1113178T1 (ru) |
DK (1) | DK2305263T3 (ru) |
ES (1) | ES2391625T3 (ru) |
HK (1) | HK1150764A1 (ru) |
IL (2) | IL202157A0 (ru) |
MX (1) | MX2009013272A (ru) |
MY (1) | MY148878A (ru) |
NZ (3) | NZ598428A (ru) |
PL (1) | PL2305263T3 (ru) |
PT (1) | PT2305263E (ru) |
RU (1) | RU2489149C2 (ru) |
SG (1) | SG182175A1 (ru) |
SI (1) | SI2305263T1 (ru) |
UY (1) | UY31125A1 (ru) |
WO (1) | WO2008154262A1 (ru) |
ZA (2) | ZA200900796B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511068B2 (en) | 2012-06-18 | 2016-12-06 | Ajou University Industry-Academic | Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0817946A2 (pt) * | 2007-09-25 | 2015-05-05 | Teva Pharma | Composições de imatinibe estável |
CZ20098A3 (cs) * | 2009-01-13 | 2010-07-21 | Zentiva, K.S. | Lékové formy inhibitoru tyrosinových kináz |
CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
WO2012080703A1 (en) * | 2010-12-15 | 2012-06-21 | Cipla Limited | Pharmaceutical composition comprising imatinib |
EA026665B1 (ru) | 2011-11-24 | 2017-05-31 | Имунекс Фарма Илак Санайи Ве Тикарет А.С. | Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением |
US9439903B2 (en) | 2012-10-25 | 2016-09-13 | Cadila Healthcare Limited | Process for the preparation of amorphous imatinib mesylate |
CN103784411B (zh) * | 2012-11-01 | 2016-03-23 | 齐鲁制药(海南)有限公司 | 一种盐酸厄洛替尼药用组合物及其制备方法 |
CA3172586A1 (en) | 2013-07-31 | 2015-02-05 | Avalyn Pharma Inc. | Aerosol imatininb compounds and uses thereof |
WO2015110949A1 (en) | 2014-01-22 | 2015-07-30 | Novartis Ag | Imatinib as cholesterol decreasing agent |
EP3752132B1 (en) * | 2018-02-13 | 2021-12-08 | Sandoz AG | Pharmaceutical composition of brigatinib |
CN109044977A (zh) * | 2018-10-26 | 2018-12-21 | 武汉工程大学 | 一种乐伐替尼固体分散体及其制备方法和制剂 |
US20220395505A1 (en) * | 2019-11-01 | 2022-12-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical Composition Comprising Quinazoline Derivative or Salt Thereof |
JP2024502990A (ja) * | 2021-01-06 | 2024-01-24 | インカーダ セラピューティクス, インコーポレイテッド | 吸入可能なイマチニブ製剤 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
RU2173172C2 (ru) * | 1997-05-05 | 2001-09-10 | Сайдекс Инк. | Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
DE60039379D1 (de) * | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmazeutische feste Dispersionen |
RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
AU2002253642B2 (en) * | 2001-04-26 | 2007-05-24 | Meiji Seika Kaisha, Ltd. | Amorphous cefditoren pivoxil composition and process for producing the same |
TW200305415A (en) * | 2002-03-22 | 2003-11-01 | Novartis Ag | Combination of organic compounds |
GB2398565A (en) * | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
AU2003237596A1 (en) * | 2003-06-02 | 2005-01-21 | Hetero Drugs Limited | Novel polymorphs of imatinib mesylate |
WO2005123076A2 (en) * | 2004-06-08 | 2005-12-29 | Vertex Pharmaceuticals, Inc. | Pharmaceutical compositions |
US7329495B2 (en) * | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
FR2873693B1 (fr) * | 2004-07-29 | 2006-09-15 | Sanofi Synthelabo | Derives d'amino-tropane, leur preparation et leur application en therapeutique |
EP1796642B1 (en) * | 2004-08-27 | 2008-05-21 | Bayer Pharmaceuticals Corporation | Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer |
MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
WO2006123223A1 (en) * | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
JP2008542397A (ja) * | 2005-06-03 | 2008-11-27 | エラン ファーマ インターナショナル リミテッド | ナノ粒子メシル酸イマチニブ製剤 |
US8067421B2 (en) * | 2006-04-27 | 2011-11-29 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
CA2662265A1 (en) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Imatinib compositions |
US20100087444A1 (en) * | 2007-03-12 | 2010-04-08 | Dr. Reddy's Laboratories Ltd. | Imatinib mesylate |
US20080234286A1 (en) * | 2007-03-20 | 2008-09-25 | Chemagis Ltd. | Stable amorphous imatinib mesylate and production process therefor |
-
2007
- 2007-06-07 PT PT10178116T patent/PT2305263E/pt unknown
- 2007-06-07 EP EP07109816A patent/EP2000139A1/en not_active Withdrawn
- 2007-06-07 SI SI200731021T patent/SI2305263T1/sl unknown
- 2007-06-07 PL PL10178116T patent/PL2305263T3/pl unknown
- 2007-06-07 EP EP10178116A patent/EP2305263B1/en not_active Not-in-force
- 2007-06-07 DK DK10178116.9T patent/DK2305263T3/da active
- 2007-06-07 ES ES10178116T patent/ES2391625T3/es active Active
-
2008
- 2008-06-05 KR KR1020127004009A patent/KR101454086B1/ko not_active IP Right Cessation
- 2008-06-05 NZ NZ598428A patent/NZ598428A/xx not_active IP Right Cessation
- 2008-06-05 BR BRPI0812442-6A patent/BRPI0812442A2/pt not_active IP Right Cessation
- 2008-06-05 RU RU2009148985/15A patent/RU2489149C2/ru not_active IP Right Cessation
- 2008-06-05 CA CA002687741A patent/CA2687741A1/en not_active Abandoned
- 2008-06-05 KR KR1020097025365A patent/KR101267782B1/ko not_active IP Right Cessation
- 2008-06-05 WO PCT/US2008/065838 patent/WO2008154262A1/en active Application Filing
- 2008-06-05 SG SG2012041802A patent/SG182175A1/en unknown
- 2008-06-05 CN CN200880018651A patent/CN101678023A/zh active Pending
- 2008-06-05 MY MYPI20094925A patent/MY148878A/en unknown
- 2008-06-05 AU AU2008262059A patent/AU2008262059B2/en not_active Ceased
- 2008-06-05 JP JP2010511312A patent/JP5380440B2/ja not_active Expired - Fee Related
- 2008-06-05 US US12/602,501 patent/US20100178336A1/en not_active Abandoned
- 2008-06-05 MX MX2009013272A patent/MX2009013272A/es active IP Right Grant
- 2008-06-05 NZ NZ581176A patent/NZ581176A/xx not_active IP Right Cessation
- 2008-06-05 CN CN201510228051.4A patent/CN104910134A/zh active Pending
- 2008-06-05 NZ NZ598427A patent/NZ598427A/xx not_active IP Right Cessation
- 2008-06-06 UY UY31125A patent/UY31125A1/es not_active Application Discontinuation
- 2008-06-06 AR ARP080102434A patent/AR067328A1/es unknown
- 2008-06-06 CL CL2008001658A patent/CL2008001658A1/es unknown
-
2009
- 2009-11-12 ZA ZA200900796A patent/ZA200900796B/xx unknown
- 2009-11-12 ZA ZA2009/07961A patent/ZA200907961B/en unknown
- 2009-11-16 IL IL202157A patent/IL202157A0/en unknown
- 2009-12-07 CO CO09139945A patent/CO6241118A2/es not_active Application Discontinuation
-
2011
- 2011-05-17 HK HK11104815.2A patent/HK1150764A1/xx not_active IP Right Cessation
-
2012
- 2012-09-24 US US13/625,345 patent/US20130022672A1/en not_active Abandoned
- 2012-10-12 CY CY20121100948T patent/CY1113178T1/el unknown
-
2013
- 2013-04-17 US US13/864,888 patent/US20130225598A1/en not_active Abandoned
- 2013-06-19 JP JP2013128722A patent/JP2013227324A/ja active Pending
-
2014
- 2014-07-15 US US14/331,703 patent/US20140323495A1/en not_active Abandoned
-
2015
- 2015-02-09 IL IL237160A patent/IL237160A0/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511068B2 (en) | 2012-06-18 | 2016-12-06 | Ajou University Industry-Academic | Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009148985A (ru) | Стабилизированные аморфные формы иматиниба мезилата | |
MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
MA30807B1 (fr) | Compositions pharmaceutiques. | |
UA100403C2 (en) | Capsule formulation | |
FI2508188T3 (fi) | Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita | |
EA200702627A1 (ru) | Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования | |
MA30598B1 (fr) | Composition pharmaceutique contenant un acide tetrahydrofolique. | |
MY147641A (en) | Fast release paracetamol tablets | |
NZ599031A (en) | A dosage form containing two or more active pharmaceutical ingredients in different physical forms | |
EP1993567A4 (en) | PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE | |
JP2015524444A5 (ru) | ||
WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
MX2009014193A (es) | Preparacion farmaceutica solida que comprende benzazepinas y metodo de produccion de la misma. | |
MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
FI4101454T3 (fi) | Koostumuksia käytettäviksi kohonneen verenpaineen hoitoon | |
PT1858494E (pt) | Nova cápsula de gelatina mole | |
WO2019046568A8 (en) | High concentration dosage forms of pridopidine | |
DE602005008128D1 (de) | Cytisinehaltiges Arzneimittel | |
MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
RU2008103213A (ru) | Орально распадающийся порошок, содержащий цилостазол и маннит | |
TW200800977A (en) | A new salt | |
RU2012112051A (ru) | Препараты ингибиторы тромбообразования | |
WO2008147169A3 (es) | Microemolsion conteniendo pirfenidona | |
WO2011093811A3 (en) | Pharmaceutical preparations comprising formoterol and fluticasone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160606 |